Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Out now in Annals of Oncology
In modern day oncology, the way we measure survival benefit is shaping how we interpret progress itself.
When the control arm is already a great option, detecting benefit requires more than a hazard ratio, and this is particularly true for 1st line combination regimens in EGFR NSCLC.
Our RMST-based reanalysis, led by Fabian Acker revisits FLAURA2 and MARIPOSA, showing that:
- Survival curves overlap for more than a year;
- The real benefit emerges late, beyond 42 months;
RMST quantifies this delayed gain, helping define when benefit begins, and how much it truly matters.”
Title: Rethinking Survival Metrics in EGFR-Mutated NSCLC: Insights from RMST Analysis of FLAURA2 and MARIPOSA
Authors: F. Acker, M. Rost, M. Sebastian, A. Cortellini
Read the Full Article on Annals of Oncology
More posts featuring Alessio Cortellini.
